Dent P, Booth L, Poklepovic A, Kirkwood JM (2021) Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res 35 34482636

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T172-p - AMPKA2 (human) ▲

Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene Orthologous residues AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ATM (human) siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib increase S-valproate, neratinib increase neratinib, S-valproate ATM (human) augment treatment-induced increase ATM KD inhibits Downstream Regulation Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited

S356-p - ATG13 (human) ▲

Modsite: TETVSNssEGRAsPH SwissProt Entrez-Gene Orthologous residues ATG13 (human): S356‑p, ATG13 iso5 (human): S389‑p, ATG13 (mouse): S355‑p, ATG13 (rat): S318‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes S-valproate, neratinib increase neratinib, S-valproate ATM (human) augment treatment-induced increase ATM KD inhibits Downstream Regulation Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited

S1981-p - ATM (human) ▲

Modsite: sLAFEEGsQSTtIss SwissProt Entrez-Gene Orthologous residues ATM (human): S1981‑p, ATM (mouse): S1987‑p, ATM (rat): S1988‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib increase S-valproate, neratinib increase neratinib, S-valproate TXN (human) inhibit treatment-induced increase neratinib, S-valproate SOD2 (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited

S52-p - eIF2-alpha (human) ▲

Modsite: MILLsELsRRRIRsI SwissProt Entrez-Gene Orthologous residues eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib increase S-valproate, neratinib increase neratinib, S-valproate ATM (human) augment treatment-induced increase ATM siRNA inhibits neratinib, S-valproate beclin 1 (human) augment treatment-induced increase Beclin 1 siRNA inhibits neratinib, S-valproate ATM (human), beclin 1 (human) augment treatment-induced increase ATM/Beclin 1 siRNA inhibits neratinib, S-valproate AMPKA1 (human) augment treatment-induced increase AMPK siRNA inhibits S-valproate, neratinib increase

Y705-p - STAT3 (human) ▲

Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene Orthologous residues STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib decrease

S758-p - ULK1 (human) ▲

Modsite: PVVFtVGsPPsGStP SwissProt Entrez-Gene Orthologous residues ULK1 (human): S758‑p, ULK1 (mouse): S757‑p, ULK1 (rat): S757‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib decrease S-valproate, neratinib decrease Downstream Regulation Effect of modification (process):  autophagy, inhibited, carcinogenesis, induced

S127-p - YAP1 (human) ▲

Modsite: PQHVRAHssPAsLQL SwissProt Entrez-Gene Orthologous residues YAP1 (human): S127‑p, YAP1 iso2 (human): S127‑p, YAP1 iso3 (human): S127‑p, YAP1 iso5 (human): S127‑p, YAP1 iso6 (human): S127‑p, YAP1 iso7 (human): S127‑p, YAP1 iso8 (human): S127‑p, YAP1 iso9 (human): S127‑p, YAP1 (mouse): S112‑p, YAP1 (rat): S112‑p, YAP1 iso3 (rat): S112‑p, YAP1 (sheep): S42‑p, YAP1 (cow): S55‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  melanocyte-skin Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neratinib increase Downstream Regulation Effect of modification (function):  intracellular localization, protein degradation Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited